Tezepelumab helps severe asthma patients reduce oral steroids over 28 weeks
New results from the Phase III SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral corticosteroid use in adults with severe oral corticosteroid-dependent asthma while maintaining asthma control and improving k…